Cite
HARVARD Citation
Ysebaert, L. et al. (2020). Overall survival benefit of symptom monitoring in real-world patients with chronic lymphocytic leukaemia treated with ibrutinib: a FiLO group study. European journal of cancer. pp. 170-172. [Online].